Press release
Oral Anti-Diabetic Drugs Market to Reach US$ 80.8 Billion by 2031, Growing at 8.0% CAGR, Driven by Rising Diabetes Prevalence and Biosimilar Expansion | DataM Intelligence
Oral Anti-Diabetic Drugs Market
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/oral-anti-diabetes-drugs-market?jd
United States Key Industry Developments
☑️ January 2026: Novo Nordisk continued strong performance of oral semaglutide (Rybelsus), with expanded insurance coverage and real-world evidence supporting its use in type 2 diabetes management.
☑️ January 2026: Merck reported increased adoption of Januvia (sitagliptin) and Janumet combinations, bolstered by new generic competition and patient assistance programs.
☑️ December 2025: Sanofi expanded its Amaryl (glimepiride) and other sulfonylurea offerings through retail pharmacy partnerships, targeting cost-conscious patients.
☑️ December 2025: Glenmark Pharma launched new fixed-dose combinations of metformin and DPP-4 inhibitors, gaining traction in the U.S. generic market.
Japan Key Industry Developments
☑️ January 2026: Japanese authorities approved additional generic versions of key DPP-4 inhibitors and biguanides, accelerating reimbursement and adoption in outpatient diabetes care.
☑️ January 2026: Local and global players, including Takeda (partnered with others), showcased advanced oral anti-diabetic portfolios at major endocrinology conferences in Tokyo.
☑️ December 2025: Growing use of SGLT2 inhibitors (oral class expansions) and metformin combinations in urban clinics, driven by rising type 2 diabetes prevalence and government metabolic health initiatives.
Key Mergers and Acquisitions
✦ Eli Lilly and Company progressed integration of recent acquisitions in metabolic health, including assets with potential crossover benefits for oral anti-diabetic pipelines (ongoing January 2026 updates).
✦ Novo Nordisk continued strategic bolt-on deals and collaborations to enhance its oral GLP-1 and combination therapy offerings for type 2 diabetes.
✦ Sun Pharma secured licensing agreements with innovators for next-generation oral anti-diabetic molecules, positioning for biosimilar and novel drug launches in 2026.
Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=oral-anti-diabetes-drugs-market
Market Segmentation Analysis
By Drug Class: Biguanides (metformin) dominate; followed by DPP-4 Inhibitors, Sulfonylureas, Alpha-glucosidase Inhibitors, Meglitinides, Dopamine-D2 Receptor Agonists, and Others.
By Dosage Type: Tablets lead; followed by Capsules and Liquid formulations.
By Distribution Channel: Retail Pharmacies and Hospital Pharmacies hold the largest shares; Online Pharmacies grow rapidly.
Regional Insights
North America commands the largest market share in the global Oral Anti-Diabetic Drugs market, supported by high diabetes prevalence, advanced healthcare infrastructure, widespread adoption of branded and generic orals, favorable reimbursement for diabetes management, and strong presence of leading pharmaceutical companies driving innovation and access.
Asia-Pacific remains the fastest-growing region, fueled by rapidly rising diabetes burden in populous countries, increasing healthcare expenditure, rapid biosimilar adoption, expanding online and retail pharmacy networks, government initiatives for chronic disease control, and aggressive market entry by global and local manufacturers.
Growth Drivers
✦ Escalating global type 2 diabetes incidence and prediabetes awareness
✦ Strong preference for oral therapies due to convenience and compliance
✦ Rapid biosimilar entry reducing costs for DPP-4 inhibitors and biguanides
✦ Advancements in fixed-dose combinations and next-generation oral agents
✦ Expanding distribution through e-commerce and retail channels
Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/oral-anti-diabetes-drugs-market?jd
Key Players
The market includes leading companies such as Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Bristol-Myers Squibb, and others.
Key Highlights (Top 5 Key Players)
✦ Novo Nordisk - Leading with oral semaglutide (Rybelsus) and strong GLP-1 class expansion.
✦ Merck - Dominating through Januvia (sitagliptin) and combination therapies.
✦ Sanofi - Strong in sulfonylureas and broad diabetes portfolio.
✦ Novartis - Advancing DPP-4 inhibitors and fixed-dose combinations.
✦ Biocon - Growing rapidly with affordable biosimilars in emerging markets.
Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd
Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Oral Anti-Diabetic Drugs Market to Reach US$ 80.8 Billion by 2031, Growing at 8.0% CAGR, Driven by Rising Diabetes Prevalence and Biosimilar Expansion | DataM Intelligence here
News-ID: 4341653 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Phenethyl Alcohol Market is set to reach US$ million by 2031, Market Size, Share …
The phenethyl alcohol market reached USD million in 2022 and is projected to witness lucrative growth by reaching up to USD million by 2031. The market is growing at a CAGR of 5.1% during the forecast period (2024-2031). Phenethyl alcohol is an organic compound with the molecular formula C6H5CH2CH2OH.
DataM Intelligence unveils its latest report on the "Phenethyl alcohol market size 2026," offering an in-depth analysis of market trends, growth drivers,…
Pressure Ulcer Devices Market Set for Strong Growth to USD 7.39 Billion by 2033, …
The Global Pressure Ulcer Devices Market size reached USD 4.11 Billion in 2024 from USD 3.87 Billion in 2023 and is expected to reach USD 7.39 Billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033.
Market growth is driven by the rising prevalence of pressure ulcers due to aging populations, increasing chronic wounds from diabetes and immobility, and higher hospital admissions worldwide. Advancements in wound care…
United States Weight Loss Therapeutics Market to Grow at 20.6% CAGR through 2033 …
According to DataM Intelligence, the global Weight Loss Therapeutics market size reached US$ 3.92 billion in 2024 and is expected to reach US$ 20.84 billion by 2033, growing at a CAGR of 20.6% during the forecast period 2025-2033. This growth is propelled by the escalating global obesity and overweight epidemic, rapid adoption of highly effective GLP-1 receptor agonists and dual GIP/GLP-1 therapies, increasing prescription of semaglutide and tirzepatide-based drugs, expanding…
Payment Processing Solutions Market to Reach US$ 198.9 Billion by 2034 at 11.7% …
The Global Payment Processing Solutions Market reached approximately US$ 66.8 billion in 2024 and is projected to grow significantly to around US$ 198.9 billion by 2034, registering a CAGR of about 11.7% during the forecast period 2025-2034. This strong growth reflects the rapid shift toward digital and cashless payments, expanding e-commerce activity, and increasing demand for secure, fast, and seamless transaction processing across industries worldwide.
Payment processing solutions facilitate the authorization,…
More Releases for Drug
Injectable Drug Delivery Market Injectable Drug Delivery Market
Leading market research firm SkyQuest Technology Group recently released a study titled ' Injectable Drug Delivery Market Global Size, Share, Growth, Industry Trends, Opportunity and Forecast 2024-2031,' This study Injectable Drug Delivery report offers a thorough analysis of the market, as well as competitor and geographical analysis and a focus on the most recent technological developments. The research study on the Injectable Drug Delivery Market extensively demonstrates existing and upcoming…
Global Advanced Drug Delivery Systems Market Size - By Product Type(Oral Drug De …
Market Overview and Report Coverage
Advanced Drug Delivery Systems (ADDS) refer to innovative technologies designed to improve the administration and efficacy of therapeutics, enhancing the way medications are delivered to targeted areas within the body. These systems aim to optimize treatment outcomes by increasing the bioavailability, reducing side effects, and facilitating controlled drug release. Employing methods such as nanoparticles, liposomes, and implantable pumps, ADDS are revolutionizing personalized medicine and expanding therapeutic…
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Pric …
Global Cancer Antibody Drug Conjugate Market Size, Drug Sales, Drug Dosage, Price, and Clinical Trials Outlook 2029 Report Highlights:
* Global Antibody Drug Conjugates Market Opportunity: > 40 Billion By 2029
* Global and Regional Antibody Drug Conjugate Market Insight
* Approved Drugs Sales Insight Global and Regional, Yearly and Quarterly, 2019 -2023
* Approved Antibody Drug Conjugates - Availability, Dosage and Price Insight
* Insight On Antibody Drug Conjugates In Clinical Trials: > 550…
Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions.
Alcohol abuse and drug…
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.
Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
